title: Adjunct pharmacotherapy in acute lung disease in children.
abstract: Mechanical ventilation, while accepted as standard therapy for critically ill infants and children with respiratory failure, has significant morbidity and mortality. While recent emphasis on low tidal volume ventilation and low airway pressures may result in decreased lung stretch and limit lung disease, adjunctive therapies have been tried to reduce the stressors of mechanical ventilation. Therapies included inhaled nitric oxide, heliox and surfactant. There are compelling physiological reasons why these drugs may be of benefit in these patients. However, our understanding of their role is hindered by studies with small numbers of patients and its use in diseases with varied pulmonary pathology. Studies have shown potential for benefit of inhaled nitric oxide in newborns with hypoxemic respiratory failure and pulmonary hypertension, surfactant in respiratory distress syndrome in preterm neonates and heliox in severe upper airway obstruction. However, the use in other respiratory conditions has led to mixed results and hence paucity of firm recommendations.
authors.affiliation: Acute and Critical Care Programs, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. nkissoon@cw.bc.ca
authors.forename: N
authors.initials: N
authors.lastname: Kissoon
authors.forename: P
authors.initials: P
authors.lastname: Skippen
mesh_terms: D000208:Acute Disease; D002648:Child; D003131:Combined Modality Therapy; D006371:Helium / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000188:drug therapy* / Q000628:therapy; D009569:Nitric Oxide / Q000627:therapeutic use*; D010100:Oxygen / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D013501:Surface-Active Agents / Q000627:therapeutic use*
chemical_list: D013501:Surface-Active Agents; D006371:Helium; D009569:Nitric Oxide; C038949:heliox; D010100:Oxygen